Chidozie Ugwumba Sells 8,717 Shares of Clene (NASDAQ:CLNN) Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 8,717 shares of the firm’s stock in a transaction that occurred on Wednesday, January 28th. The stock was sold at an average price of $4.91, for a total transaction of $42,800.47. Following the sale, the insider owned 580,329 shares of the company’s stock, valued at $2,849,415.39. This represents a 1.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Tuesday, January 27th, Chidozie Ugwumba sold 4,139 shares of Clene stock. The stock was sold at an average price of $5.08, for a total value of $21,026.12.
• On Monday, January 26th, Chidozie Ugwumba sold 6,418 shares of Clene stock. The stock was sold at an average price of $5.02, for a total value of $32,218.36.
• On Friday, January 23rd, Chidozie Ugwumba sold 5,556 shares of Clene stock. The shares were sold at an average price of $5.27, for a total value of $29,280.12.
• On Thursday, January 22nd, Chidozie Ugwumba sold 12,665 shares of Clene stock. The stock was sold at an average price of $5.32, for a total value of $67,377.80.
• On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The stock was sold at an average price of $5.05, for a total value of $61,200.95.
• On Tuesday, January 20th, Chidozie Ugwumba sold 12,432 shares of Clene stock. The shares were sold at an average price of $4.80, for a total transaction of $59,673.60.
• On Friday, January 16th, Chidozie Ugwumba sold 7,923 shares of Clene stock. The stock was sold at an average price of $5.13, for a total transaction of $40,644.99.
• On Thursday, January 15th, Chidozie Ugwumba sold 12,563 shares of Clene stock. The shares were sold at an average price of $5.10, for a total transaction of $64,071.30.
• On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The shares were sold at an average price of $5.12, for a total transaction of $100,459.52.
• On Tuesday, January 13th, Chidozie Ugwumba sold 26,105 shares of Clene stock. The stock was sold at an average price of $4.89, for a total transaction of $127,653.45.

Clene Stock Performance

Clene stock opened at $4.17 on Friday. The company has a market capitalization of $45.24 million, a PE ratio of -1.23 and a beta of 0.87. Clene Inc. has a fifty-two week low of $2.28 and a fifty-two week high of $13.50. The firm has a 50 day moving average price of $6.45 and a 200 day moving average price of $6.52.

Clene (NASDAQ:CLNN) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.06 million. As a group, equities research analysts forecast that Clene Inc. will post -5.19 earnings per share for the current year.

Institutional Trading of Clene

Hedge funds and other institutional investors have recently bought and sold shares of the business. Scoggin Management LP boosted its position in shares of Clene by 75.1% during the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock worth $1,506,000 after acquiring an additional 107,250 shares in the last quarter. Lunt Capital Management Inc. boosted its holdings in Clene by 2.5% in the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock valued at $315,000 after purchasing an additional 1,250 shares in the last quarter. Jones Financial Companies Lllp acquired a new position in Clene in the third quarter valued at approximately $29,000. Finally, Jane Street Group LLC purchased a new position in Clene in the second quarter valued at approximately $47,000. 23.28% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on CLNN. D. Boral Capital reiterated a “buy” rating and set a $23.00 target price on shares of Clene in a report on Friday, January 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Clene in a research note on Friday, January 9th. UBS Group reissued a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Finally, Benchmark restated a “buy” rating on shares of Clene in a report on Thursday, December 4th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $32.60.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).